27100

009013

UNITED STATES ENVIRONMENTAL PROTECTION AGENCY
WASHINGTON, D.C. 20460

OFFICE OF
PESTICIDES AND TOXIC SUBSTANCES

July 9, 1990

MEMORANDUM

SUBJECT: EPA Reg. No./File Symbol 10182- RUN
Cyfluthrin 70% Technical

FROM: Olga Odiott OO E 7/10/90
Precautionary Review Section
Registration Support Branch
Registration Division (H75-05C)

TO: George DeRocco (PM 15)
Insecticide - Rodenticide Branch
Registration Division (H75-05C)

APPLICANT: ICI Americas
Agricultural Products Division
Concord Pike & New Murphy Rd.
Wilmington, DE 19897

FORMULATION FROM LABEL:

Active Ingredient(s):	% by wt.
α-Cyano-(3-phenoxyphenyl)methyl(±)-cis,trans-3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropanecarboxylate	70%
Inert Ingredient(s):	30%
Total	100.0%

0091 10/6

BACKGROUND

ICI Americas Inc. submitted an acute inhalation study on Reg. No. 10182-RUN to fullfil the acute toxicity data requirements for registration. The study was conducted at ICI Central Toxicology Lab, Cheshire, UK. MRID No. 413036-01.

The product was characterized as follows in a previous review: acute oral- Cat II; acute dermal- Cat III; acute eye- Cat III; skin irritation- Cat IV; skin sensitization- a sensitizer.

RECOMMENDATION

RSB/PRS finds the study supplementary data. The MMAD's are greater than 1.0 μ. The Agency requires at least 25% of the particles to meet the size requirement. A Memo by Dr. Stanley Gross on acute inhalation toxicity testing is included for registrant's reference.

LABELING

Statements of practical treatment:

The last sentence of the "If in eyes" statement should read: "Call a physician if irritation persists."

Precautionary statements:

Delete: "...goggles, or full face shield." Use of goggles is not required for this product's formulation.

Add: "Prolonged or frequently repeated skin contact may cause allergic reactions in some individuals."

Further label revisions may be necessary upon submittance of outstanding data.

Note to PM:

In a precautionary labeling review dated 3-8-88, the dermal sensitization study with MRID No.403777-01 was classified as a moderate sensitizer. The letter sent to the registrant on May 23, 1988 indicated the product was a non-sensitizer and precautionary labeling regarding sensitization was not necessary.

009013

DATA REVIEW FOR ACUTE INHALATION TOXICITY TESTING (§81-3)

Product Manager: (15)
MRID No.: 413036-01
Testing Laboratory: ICI Central Tox Lab.
Author(s): A. Bramer
Species: Alistar derived albino Rats
Sex : 15 males, 15 females Weight: 201 - 268 gm
Source: Alderley Park, Cheshire, UK
Test Material: Cypermethrin (technical) 92.9% AI.
Quality Assurance (40 CFR §160.12): attached

Reviewer: O. Odiott
Report Date: 24 Apr. 1989
Report No. URO862-

Summary:

1. LC_{50} (mg/kg): Males = _____; Females = _____; Combined = _____
2. The estimated LC_{50} is _____
3. Mean Concentration: _____
4. Tox. Category : _____. Classification: Supplementary

Procedure (Deviations From §81-2): MMAD greater than 1.0μ. *animals were killed due to severe clinical effects on days 1 and 2 following exposure

Results:

Reported Mortality

Exposure Concentration (mg/L)	NUMBER KILLED/NUMBER TESTED) Males	Females	Combined
0.53 mg/l	0/5	0/5	0/10
1.05 mg/l	4/5	1/5	2/10
1.98 mg/l	5/5	5/5	10/10
MMAD = 3.95μ, 4.68μ			
and 5.20μ respectively			

Symptomology & Gross Necropsy Findings:

lacrymation, salivation, reduced breathing rate, increased breathing depth, reduced response to sound, intermittent tail erections, hunched posture, piloerection, chromodacryorrhea, shaking and reduced stability. No abnormalities reported for gross necropsy examinations.

0003

Cypermethrin Review

Page _____ is not included in this copy.

Pages 4 through 6 are not included in this copy.

The material not included contains the following type of information:

_____ Identity of product inert ingredients.

_____ Identity of product impurities.

_____ Description of the product manufacturing process.

_____ Description of quality control procedures.

_____ Identity of the source of product ingredients.

_____ Sales or other commercial/financial information.

X A draft product label.

_____ The product confidential statement of formula.

_____ Information about a pending registration action.

_____ FIFRA registration data.

_____ The document is a duplicate of page(s) _____.

_____ The document is not responsive to the request.

The information not included is generally considered confidential by product registrants. If you have any questions, please contact the individual who prepared the response to your request.